May 19, 2025
Amid a wave of layoffs and major federal research funding cuts under the Trump administration, many US-based scientists are reevaluating their careers and considering relocation. According […]
May 19, 2025
TOPLINE: In a UK biobank study, men had significantly higher risks for oesophageal adenocarcinoma and cancers of the bladder, rectum, kidney, and liver than women, suggesting […]
May 19, 2025
Rates of certain cancers in the United States — including breast, colorectal, and thyroid cancers — increased between 2010 and 2019 among patients aged less than […]
May 19, 2025
New data support integrating tumor-infiltrating lymphocyte levels with nodal status to improve risk stratification in women with triple-negative breast cancer (TNBC) and pathological complete response (pCR) […]
May 16, 2025
The US Food and Drug Administration has approved two new indications for the PD-1-blocking antibody, retifanlimab-dlwr (Zynyz, Incyte), both for locally recurrent or metastatic squamous cell […]
May 16, 2025
TOPLINE: A combination of targeted treatment and immunotherapy has revolutionized Philadelphia chromosome–positive acute lymphoblastic leukemia management, achieving long-term survival rates of 75%-80% without systemic chemotherapy or […]
May 16, 2025
TOPLINE: Germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs) show dependence on DOT1L and EZH2, with combined targeting offering potential as an alternative differentiation-based therapy. DOT1L […]
May 16, 2025
Combination therapy with imlunestrant and the CDK4/6 inhibitor abemaciclib led to a significant progression-free survival (PFS) benefit compared with imlunestrant alone in women with estrogen receptor […]
May 15, 2025
The US Food and Drug Administration (FDA) has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis, AbbVie) for locally advanced or metastatic nonsquamous non–small cell lung cancer […]